λ1 |
pDC |
increase the expression of the homing molecules CCR7 and CD62L; upregulate co-stimulatory molecules CD80 and ICOS-L, and reduce stimulation of IL-10, IL-13, and IFN-γ production from allogeneic T cells |
contribute to pDC activity and prolong pDC survival |
58, 59 |
|
λ1, λ2 |
mDC (without LPS) |
induce partial maturation of DCs; high levels of major MHC class I and MHC class II; express CCR7; low levels of costimulatory molecules, and retained phagocytic ability |
induce partial maturation of mDCs |
62 |
|
λ1, λ2 |
mDC |
profoundly inhibit the generation of Th2 and Th17 responses; enhance Th1 polarization, and augment IL-12 secretion |
promote mDC maturation |
60, 61 |
|
λ1 |
CD4+ T cell |
alter the Th1/Th2 development of naive human T cells; diminish the development of Th2 cells and lower the secretion of IL-13, and induce CD3+ T cell apoptosis |
inhibit Th2, promote Th1, and induce apoptosis |
60, 64, 73 |
|
λ1, λ2 |
Treg |
IL-2-dependent proliferation of CD4+CD25+Foxp3+ T cells |
induce proliferation of Treg |
62 |
|
λ3 |
CD8+ T cell |
increase CTL killing activity, and enhance antigen-specific cytolytic degranulation |
promote killing activity |
65, 66 |
|
λ1, λ2/3 |
NK |
do not enhance NK cytotoxic activity and chemotaxis directly |
no direct influence on NK |
67, 68, 74 |
|
λ1 |
PBMC |
elevate chemokines mRNA levels of CXCL9, CXCL10, and CXCL11, and upregulate IL-6, IL-8, and IL-10 |
activate PBMC |
70, 71 |
|
λ1 |
monocyte |
upregulate IL-6, IL-8, and IL-10; change morphology, and more motile |
activate monocyte |
71 |
|
λ1 |
macrophage |
upregulate IL-6, IL-8, and IL-10; increase TLR-induced IL-12p40 production, and upregulate IFN-γR1 |
activate macrophage |
35, 71 |
|
λ2/3 |
B cell |
enhance TLR7 on B cells |
unclear |
75 |